Shanghai LePure Biotechnology Co., Ltd.
PrivateLast Round
Series C
Jan 17, 2023
Est. Valuation
$261.54M
Total Funding Raised
$125.55M
Company Overview
Shanghai LePure Biotechnology Co., Ltd. is a biotechnology company that provides single-use bioprocessing solutions, including consumables, equipment, and validation services, for the biopharmaceutical industry.
Sector
Healthcare & Life Sciences
Verticals
Pharma Supply Chain, Biotech Equipment, Clean Manufacturing, Advanced Materials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai LePure Biotechnology Co., Ltd. Comparables
Compare Shanghai LePure Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Duoning Biotechnology | 88% | |
| BioLink | 84% | |
| Cobetter Filtration | 83% |
Shanghai LePure Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 17, 2023 | ||||
| Strategic | Nov 25, 2022 | ||||
| Strategic | Jul 18, 2022 | ||||
| VC Round | Feb 18, 2022 | ||||
| Series B Extension | Dec 18, 2021 | ||||
Series B | Apr 2, 2021 |
Shanghai LePure Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | VC Round, Series C, Strategic |
| Hillhouse Investment | Series B Extension |
| Goldman Sachs (Asia) LLC | Strategic |
| Huimei Capital | Strategic, Series B Extension, Series C |
| Goldman Sachs Asset Management Private Equity | Series C |
| Legend Capital | Series B Extension, Series B |
| CICC Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 17, 2023
$126M round led by Goldman Sachs, Novo Holdings, and General Atlantic.
- Nov 25, 2022
Raised a strategic round with participation from Huimei Capital.
Shanghai LePure Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Shanghai LePure Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai LePure Biotech Co., Ltd. a public or private company?
Shanghai LePure Biotech Co., Ltd. is a private company.
What is the current stock price of Shanghai LePure Biotech Co., Ltd.?
Shanghai LePure Biotech Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Shanghai LePure Biotech Co., Ltd. worth (valuation)?
Shanghai LePure Biotech Co., Ltd.'s valuation is estimated at $261.5M based on funding round data.
Can I buy Shanghai LePure Biotech Co., Ltd. stock?
Shanghai LePure Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Shanghai LePure Biotech Co., Ltd.'s last funding round?
Shanghai LePure Biotech Co., Ltd.'s most recent funding round was Series C on April 2, 2021.
Who are the main investors in Shanghai LePure Biotech Co., Ltd.?
Key investors in Shanghai LePure Biotech Co., Ltd. include Goldman Sachs Asset Management Private Equity, Legend Capital, Novo Holdings, General Atlantic.
Will Shanghai LePure Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai LePure Biotech Co., Ltd..
How can I track Shanghai LePure Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai LePure Biotech Co., Ltd.'s secondary market activity and sign up for updates.